(-)PPAP: a new and selective ligand for sigma binding sites.

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Investigating sigma (σ) binding sites is crucial for understanding neurological processes.
• Existing agents often lack high affinity or selectivity for σ sites, binding also to phencyclidine (PCP) sites or dopamine receptors.
• Some agents exhibit unwanted dopaminergic activity in vivo.

Purpose of the Study:

• To introduce a novel high-affinity and selective sigma (σ) ligand, (-)PPAP (R(-)-N-(3-phenyl-n-propyl)-1-phenyl-2-aminopropane hydrochloride).
• To characterize the binding profile of (-)PPAP in comparison to known ligands and receptors.
• To assess the in vivo behavioral effects of (-)PPAP, particularly its relationship to amphetamine.

Main Methods:

• Radioligand binding assays were used to determine the affinity of (-)PPAP for sigma (σ) sites.
• Competitive binding assays were performed to assess (-)PPAP's affinity for phencyclidine (PCP) sites and D1/D2 dopamine receptors.
• In vivo behavioral studies in rats trained to discriminate S(+)amphetamine were conducted to evaluate stimulus effects.

Main Results:

• (-)PPAP demonstrated high affinity for sigma (σ) sites (IC50 = 24 nM).
• (-)PPAP exhibited remarkable selectivity, with very low affinity for PCP sites (IC50 > 75,000 nM) and dopamine receptors (IC50 > 5,000 nM).
• (-)PPAP did not produce or antagonize amphetamine-like stimulus effects in rats.

Conclusions:

• (-)PPAP is a highly potent and selective sigma (σ) ligand.
• Its distinct binding profile makes it a valuable research tool for studying sigma (σ) receptor function.
• (-)PPAP's lack of amphetamine-like effects suggests a differentiated pharmacological profile.